Clinical Trials Logo

Clinical Trial Summary

BACKGROUND: In patients with high risk stage II and stage III colon cancer (CC), curative surgery followed by adjuvant chemotherapy with FOLFOX or CAPOX regimens has become a standard treatment. However, 20 to 30 % of these patients will develop distant metastasis, which ultimately result in death. Perioperative chemotherapy is a promising strategy with potential benefits that could be more effective at eradicating micrometastases. Moreover, shrinking tumor before surgery not only facilitate removal of all the tumor by the surgeon but also reduce tumor cell spreading during the procedure. With recent advances in radiology, preoperative computed tomography allows a good prediction of tumor stage (wall penetration and nodal involvement) prior to surgery. The investigators conducted the present randomized study to explore whether perioperative chemotherapy with FOLFOXIRI regimen compared with postoperative chemotherapy could improve disease-free survival in patients with radiologically staged, High-risk, but resectable Stage II or III colon cancer. OBJECTIVE: The primary objective of this study is to evaluate the efficacy of perioperative chemotherapy with FOLFOXIRI regimen compared to postoperative chemotherapy in patients with High-risk Resectable Stage II and III colon cancer. Secondary objectives are efficacy in terms of R0 resection rate, overall survival (OS), relapse-free survival (RFS), down-staging of primary tumors, and tolerability of perioperative therapy and postoperative complications.


Clinical Trial Description

This trial is a a two-arm, multicenter, open labelled, prospective, randomized phase III studies. Eligible patients with High-risk Resectable Stage II and III (T4 or T3 with extramural depth≧5 mm) colon cancer patients will be randomly assigned, in a 2:1 ratio, to receive either perioperative or postoperative chemotherapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05194878
Study type Interventional
Source Sun Yat-sen University
Contact
Status Recruiting
Phase Phase 3
Start date December 1, 2021
Completion date December 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Completed NCT00309530 - Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C Phase 3
Completed NCT04342676 - Lymph Node Ratio and Kras Mutation in R Colon Cancer Phase 3
Enrolling by invitation NCT05179889 - Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer Phase 2/Phase 3
Withdrawn NCT05433402 - Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer Phase 1/Phase 2
Recruiting NCT06108310 - ArTificial inTelligence-based RAdiogenomics in Colon Tumors
Withdrawn NCT05310565 - The Effects of Chiropractic in Adults With Colon Cancer N/A
Not yet recruiting NCT04488159 - Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer Phase 3